Search Results
240 results
Your search is now limited to «Sanofi» expert search.
Biomunex Pharmaceuticals has signed a licensing agreement with Sanofi for the development of bi-specific and multi-specific antibody therapeutics.
More from Pharmaceutical Business Review:
FiercePharma 01/15/2019 15:05
Here is some other vaccine news of note for the week: > The FDA approved an expanded use for Sanofi's Tdap vaccine Adacel to allow for repeat vaccinations.
More from FiercePharma:
Contract Pharma 01/15/2019 08:59
Under the terms of the agreement, Sanofi will have access to Biomunex' proprietary technology to generate and optimize bi- and multi-specific antibody therapeutics.
More from Contract Pharma:
NASDAQ 01/14/2019 18:06
In trading on Monday shares of Sanofi Symbol SNY crossed below their 200 day moving average of 42 05 changing hands as low as 41 61 per share Sanofi shares are currently trading off about 1 9 on the day The chart below shows the one year performance of SNY shares versus its 200.
More from NASDAQ:
WN.com 01/11/2019 18:11
11.01.2019 22:30:00 CET Availability of the Pre-quarterly Results Communication Paris, France - January 11, 2019 - Sanofi announced today that its Pre-Quarterly Results Communication document is available on the 'Investors' page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q4-results-2018 As for each quarter, Sanofi prepared this document to assist in the financial modeling of the Group's quarterly results.
More from WN.com:
GlobeNewswire 01/11/2019 16:31
Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.
More from GlobeNewswire:
About Sanofi Sanofi is dedicated to supporting people through their health challenges.
More from Middle East North Africa Financial Network (MENAFN):
FierceBiotech 01/10/2019 08:44
Sanofi pays Regeneron $462M to exit immuno-oncology R&D pact Sanofi is paying Regeneron $462 million (€404 million) to exit the immuno-oncology pact it formed in 2015.
More from FierceBiotech:
PR Newswire 01/09/2019 08:00
VANCOUVER, Wash., Jan. 9, 2019 /PRNewswire/ -- AbSci, a global leader in biotherapeutic discovery and manufacturing technologies, today announced a collaboration with Sanofi.
More from PR Newswire:
PharmaTimes 01/09/2019 05:40
Regeneron and Sanofi have restructured their global immuno-oncology discovery and development agreement for new immuno-oncology cancer treatments, with Sanofi set to pay $462 million to end the collaboration early.
More from PharmaTimes:
BioPharma-Reporter 01/08/2019 09:09
Sanofi will pay Regeneron $462m (€402m) representing the balance of payments due under the original immune-oncology agreement, covering the Sanofi share of the discovery program costs for the last quarter of 2018.
More from BioPharma-Reporter:
PharmaBiz.com 01/07/2019 22:35
Regeneron Pharmaceuticals, Inc and Sanofi have restructured their global immuno-oncology discovery and development agreement for new immuno-oncology cancer treatments.
More from PharmaBiz.com:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications